But the burst of renewed interest and activity around cancer vaccines is encouraging. And personalized vaccines might have a ...

Genentech parent Roche has shaved one of five projects from its drug portfolio since Q3 2023. Here’s what that means for the ...

The firm bought the location of culinary school San Francisco Baking Institute for $36.5 million, according to a deed filed ...

However, a single enormous deal for California property owned by Genentech pushed the average sale price up 22% from the ...

Shares of Adaptimmune Therapeutics were down 10% Friday after biotech powerhouse Genentech terminated a cell therapy partnership with the company valued at up to $3 billion. The collaboration and ...

In the same week that Genentech confirmed it's cutting 3% of its staff, the Roche subsidiary has terminated a cell therapy partnership with Adaptimmune Therapeutics worth up to $3 billion biobucks.

Biotech giants Genentech and Sanofi are laying off hundreds of workers at their facilities in South San Francisco. The San Francisco Business Times reported Genentech's parent company Roche would ...

Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Read more about ADAP ...

The paper-based KeepSight Journal from the International Macular and Retinal Foundation, Genentech's MyVisionTrack app, and ...

Data from the Phase III OCARINA II study shows the subcutaneous version of Ocrevus achieved near-complete suppression of ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa ® (alectinib) for adjuvant treatment ...

Real-world US claims-based data show major gaps in the care and management of three major neurologic diseases – Alzheimer's, ...